Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Annals of Hematology

Volumn 92, Issue 11, 2013, Pages 1485-1493

  Taher, Ali T ^a   Porter, John B ^b   Viprakasit, Vip ^c   Kattamis, Antonis ^d   Chuncharunee, Suporn ^e   Sutcharitchan, Pranee ^f   Siritanaratkul, Noppadol ^c   Galanello, Renzo ^g   Karakas, Zeynep ^h   Lawniczek, Tomasz ⁱ   Habr, Dany ⁱ   Ros, Jacqueline ⁱ   Zhu, Zewen ⁱ   Cappellini, M Domenica ^j  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF ATHENS   (Greece)

^e MAHIDOL UNIVERSITY   (Thailand)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g UNIVERSITY OF CAGLIARI   (Italy)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Deferasirox; Iron chelation; Iron overload; Non transfusion dependent thalassemia

Indexed keywords

DEFERASIROX; FERRITIN; PLACEBO; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; FEVER; FOLLOW UP; GASTROENTERITIS; HEADACHE; HEPATITIS; HUMAN; IRON OVERLOAD; LIVER IRON CONCENTRATION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; NON TRANSFUSION DEPENDENT THALASSEMIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THALASSA STUDY; THALASSEMIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; BLOOD; BLOOD TRANSFUSION; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

BENZOATES; BLOOD TRANSFUSION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; PROSPECTIVE STUDIES; THALASSEMIA; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84885662128     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1808-z     Document Type: Review

References (18)

1. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD (2010) Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 150:486-489
2. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica 96:1605-1612
3. Akrawinthawong K, Chaowalit N, Chatuparisuth T, Siritanaratkul N (2011) Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology 16:113-122
4. Chan JC, Chim C-S, Ooi CG, Cheung B, Liang R, Chan T-K, Chan V (2006) Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 133:198-205
5. Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A (1981) Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr 137:267-271
6. Ladis V, Berdousi H, Gotsis E, Kattamis A (2010) Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol 151:504-508
7. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM (1992) Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79:2741-2748
8. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O, Hoffbrand AV (2003) Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 122:305-310
9. Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanakatkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y et al (2012) Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 120:970-977
10. Voskaridou E, Plata E, Douskou M, Papadakis M, Delaki EE, Christoulas D, Terpos E (2010) Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol 148:332-334
11. Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M, Terpos E (2011) Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/beta-thalassemia. Ann Hematol 90:11-15
12. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855-861
13. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G (2000) Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343:327-331
14. Agresti A, Coull BA (1998) Approximate is better than «exact» for interval estimation of binomial proportions. Am Stat 52:119-126
15. Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P, Kavouklis M, Aessopos A, Sakellaropoulos N, Karagiorga M, Kalotychou V, Loukopoulos D (2000) Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 85:115-117
16. Musallam KM, Cappellini MD, Wood JC, Taher AT (2012) Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev 26(Suppl 1):S16-S19
17. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanakatkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J et al. (2012) Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study. Haematologica 97 (Suppl 1):abst 0927
18. Thalassaemia International Federation. Guidelines for the management of non transfusion dependent thalassaemia (NTDT). 2013. Available at: http://www.thalassaemia.org.cy/wordpress/wp-content/uploads/2013/05/ NTDT-BOOKLET-FINAL-PDF.pdf.